Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. Misses on Revenue, Stock Down 31.93%

Aurinia Pharmaceuticals reported a narrower loss per share than expected, but the lack of revenue figures and guidance likely contributed to a significant drop in the stock price. Investors reacted negatively, leading to a decline of nearly 32%. The absence of management commentary leaves uncertainty about future performance and strategy.